For SC-NEC given cis/carboplatin and etoposide, RB1 deletion predicted disease control (0% immediate progression vs 38%, p = 0.003) and TP53 mutation was associated with longer OS (10.2 vs 7.3 m, p = 0.011). This evidence concerns the gene RB1 and neuroendocrine carcinoma.